Has Charles Mango, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,883 in general payments to Charles Mango, MD across 30 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charles Mango, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charles Mango, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charles Mango, MD

Ophthalmology · Syracuse, NYNPI 1285637611

Payments from drug & device makers

$2,883in general payments, 2019–2025

Across 30 payments — averaging $96.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eyepoint US, Inc.$2K
Dutch Ophthalmic, USA$238
Apellis Pharmaceuticals, Inc.$218
Alimera Sciences, Inc.$116
Carl Zeiss Meditec, Inc.$58
Regeneron Healthcare Solutions, Inc.$42
plus $141 from 5 others

What the payments were for

Consulting fees$1,85064%
Food & beverage$1,03336%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eyepoint US, Inc.	7	$2,071
Dutch Ophthalmic, USA	2	$238
Apellis Pharmaceuticals, Inc.	3	$218
Alimera Sciences, Inc.	9	$116
Carl Zeiss Meditec, Inc.	1	$58
Regeneron Healthcare Solutions, Inc.	2	$42
Genentech USA, Inc.	2	$40
AbbVie	1	$33
ANI Pharmaceuticals, Inc.	1	$25
Coherus Oncology, Inc.	1	$25
Astellas Pharma US Inc	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,883 in reported general payments places this provider in the 65th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024

$158,047

Medicare patients

334

Services billed

1,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ofloxacin	51	$458
Levothyroxine Sodium	13	$96

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Syracuse

Douglas JabsNew York$24.3M
David RubaltelliBrooklyn$8.9M
Philip FerroneGreat Neck$5.8M
Eric DonnenfeldGarden City$2.6M
Nathan RadcliffeNew York$2.4M
Glenn StollerRockville Centre$2.1M
Richard SpaideNew York$1.7M
Paul HartmanRochester$1.6M
Jason SlakterNew York$1.2M
David ChuNew York$1.2M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →